clofibrate has been researched along with Hyperlipoproteinemia Type IV in 52 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Hyperlipoproteinemia Type IV: A hypertriglyceridemia disorder, often with autosomal dominant inheritance. It is characterized by the persistent elevations of plasma TRIGLYCERIDES, endogenously synthesized and contained predominantly in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). In contrast, the plasma CHOLESTEROL and PHOSPHOLIPIDS usually remain within normal limits.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of a combination of clofibrate and inositol nicotinate (Liporeduct forte, Liporeduct) on lipids and lipoproteins in 20 patients with primary hyperlipoproteinemia (10 type IIa, 7 type IV and 3 tyV) was investigated over a period of 16 weeks." | 7.66 | [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. ( Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1983) |
| "The effect of a combination of clofibrate and inositol nicotinate (Liporeduct forte, Liporeduct) on lipids and lipoproteins in 20 patients with primary hyperlipoproteinemia (10 type IIa, 7 type IV and 3 tyV) was investigated over a period of 16 weeks." | 3.66 | [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. ( Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1983) |
| "Ten patients with type III and 10 with type IV hyperlipoproteinemia participated in a comparative open cross-over study of the effect of acipimox (750 mg/day) and clofibrate (2 g/day) on lipoproteins, apoliproproteins and postheparin lipase activities during 6 weeks." | 2.66 | A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia. ( Demacker, PN; Stalenhoef, AF; Stuyt, PM; Van 't Laar, A, 1985) |
| "Oral carnitine has been reported to have a lipid-lowering effect with concomitant elevation of high density lipoprotein cholesterol (HDL-C) levels in normo- and hyperlipidemic individuals." | 1.27 | Plasma carnitine and lipid-lowering drugs. ( Davignon, J; Nestruck, AC; Pande, SV, 1985) |
| "Ciprofibrate was convenient to take and was without subjective side effects." | 1.26 | Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. ( Olsson, AG; Orö, L, 1982) |
| "Treatment with clofibric acid over a long period of time may well give rise to additional reactions through influences exerted upon the insulin level." | 1.26 | [Effect of clofibric acid on fatty acid metabolism in HLP patients in the 2d half of life]. ( Reuter, W, 1982) |
| " All patients were dietary adapted before the preliminary wash-out period of 4 weeks and received etofylline clofibrate in a dosage of 500 mg/day (2x1 capsule) over 4 weeks, and 750 mg/day (3 x 1 capsule) over further 4 months." | 1.26 | [Clinical effects and tolerance of etofylline clofibrate]. ( Metz, G; Specker, M; Ziegler, WJ, 1980) |
| "Fenofibrate was also found to normalize platelet aggregation in patients with type IIb HLP." | 1.26 | [Pharmacology of fenofibrate (author's transl)]. ( Kritchevsky, D, 1980) |
| "Bezafibrate is a potent lipid-lowering agent of the new generation." | 1.26 | Clinical experience with bezafibrate. ( Hausmann, L; Kaffarnik, H; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980) |
| "Niceritrol treatment significantly reduced the Chol/TG ratio in VLDL while no such effect was seen during clofibrate administration." | 1.26 | Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease. ( Borberg, J; Gustafsson, IB; Lithell, H; Vessby, B, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 50 (96.15) | 18.7374 |
| 1990's | 2 (3.85) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaffarnik, H | 2 |
| Schneider, J | 2 |
| Schubotz, R | 2 |
| Zöfel, P | 1 |
| Hausmann, L | 2 |
| Goebel, KM | 1 |
| Sirtori, M | 1 |
| Montanari, G | 1 |
| Gianfranceschi, G | 1 |
| Malacrida, MG | 1 |
| Battistin, P | 1 |
| Morazzoni, G | 1 |
| Tremoli, E | 1 |
| Colli, S | 1 |
| Maderna, P | 1 |
| Sirtori, CR | 1 |
| Gawrońska-Szklarz, B | 1 |
| Kalinowski, W | 1 |
| Wójcicki, J | 1 |
| Kesäniemi, YA | 1 |
| Grundy, SM | 1 |
| Hutt, V | 3 |
| Wechsler, JG | 2 |
| Klör, HU | 3 |
| Ditschuneit, H | 3 |
| Soler, J | 1 |
| Vinzia, C | 1 |
| Gómez, JM | 1 |
| Morató, J | 1 |
| Jäger, E | 1 |
| Kefalides, A | 1 |
| Clopath, P | 1 |
| Sinzinger, H | 1 |
| Miettinen, TA | 1 |
| Huttunen, JK | 1 |
| Ehnholm, C | 1 |
| Kumlin, T | 1 |
| Mattila, S | 1 |
| Naukkarinen, V | 1 |
| Vogelberg, KH | 1 |
| Dannehl, K | 1 |
| Gries, FA | 1 |
| Reuter, W | 2 |
| Neuman, MP | 1 |
| Kurlat, MI | 1 |
| Neuman, J | 1 |
| Nash, DT | 1 |
| Carvalho, AC | 1 |
| Lees, RS | 1 |
| Olsson, AG | 1 |
| Orö, L | 1 |
| Altomonte, L | 2 |
| Mingrone, G | 2 |
| Negrini, A | 1 |
| De Cunto, F | 1 |
| Greco, AV | 2 |
| Ferreira, IJ | 1 |
| del Rio, A | 1 |
| González-Viejo, N | 1 |
| Vicens, B | 1 |
| Havel, RJ | 1 |
| Kane, JP | 1 |
| Ferreira Montero, IJ | 1 |
| Gutiérrez Martín, M | 1 |
| del Río Ligorit, A | 1 |
| Casasnovas Lenguas, JA | 1 |
| Cornudella Lacasa, R | 1 |
| Schwandt, P | 2 |
| Weisweiler, P | 2 |
| Drosner, M | 1 |
| Janetschek, P | 1 |
| Schwartzkopff, W | 3 |
| Luley, C | 2 |
| Scheffler, W | 2 |
| Lehmann-Leo, W | 1 |
| Schilling, A | 3 |
| Wegscheider, K | 1 |
| Vessby, B | 2 |
| Lithell, H | 2 |
| Ledermann, H | 1 |
| Naruszewicz, M | 2 |
| Nowicka, G | 1 |
| Szostak, WB | 2 |
| Kłosiewicz-Latoszek, L | 1 |
| Ziegler, WJ | 2 |
| Metz, G | 1 |
| Specker, M | 1 |
| Vorberg, G | 1 |
| Ditschuneit, HH | 1 |
| Kritchevsky, D | 1 |
| Sale, JK | 1 |
| Johnstone, JH | 1 |
| Mühlfellner, G | 1 |
| Mühlfellner, O | 1 |
| Ghirlanda, G | 1 |
| Manna, R | 1 |
| Rebuzzi, A | 1 |
| Pala, MA | 1 |
| Calder, D | 2 |
| Wolfe, BM | 1 |
| Ahuja, SP | 1 |
| Marliss, EB | 1 |
| Cybulska, C | 1 |
| Kozłowska, M | 1 |
| Chotkowska, E | 1 |
| Sznajderman, M | 1 |
| Brook, JG | 1 |
| Lavy, A | 1 |
| Aviram, M | 1 |
| Zinder, O | 1 |
| Noseda, G | 1 |
| Fragiacomo, C | 1 |
| Weidmann, P | 1 |
| Bachmann, C | 1 |
| Rajecová, E | 1 |
| Klimes, I | 1 |
| Seböková, E | 1 |
| Rychnavská, E | 1 |
| Pleváková, L | 1 |
| Linke-Cvrkalová, A | 1 |
| Langrová, H | 1 |
| Gustafsson, IB | 1 |
| Borberg, J | 1 |
| Colombo, L | 1 |
| Monarca, A | 1 |
| Goldberg, D | 1 |
| Zanetta, R | 1 |
| Bolzano, K | 1 |
| Krempler, F | 1 |
| Schellenberg, B | 1 |
| Schlierf, G | 1 |
| Oikawa, S | 1 |
| Rodriguez, F | 1 |
| López, IM | 1 |
| Jover, E | 1 |
| Gotto, AM | 1 |
| Jones, PH | 1 |
| Scott, LW | 1 |
| Brown, WV | 1 |
| Stuyt, PM | 1 |
| Stalenhoef, AF | 1 |
| Demacker, PN | 1 |
| Van 't Laar, A | 1 |
| Lipovetskiĭ, BM | 1 |
| Triufanov, VF | 1 |
| Teriukova, NP | 1 |
| Nestruck, AC | 1 |
| Pande, SV | 1 |
| Davignon, J | 1 |
| Parker, F | 1 |
3 reviews available for clofibrate and Hyperlipoproteinemia Type IV
| Article | Year |
|---|---|
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
Therapy of hyperlipidemic states.
Topics: Cholesterol, Dietary; Cholestyramine Resin; Clofibrate; Colestipol; Dietary Fats; Drug Therapy, Comb | 1982 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr | 1986 |
9 trials available for clofibrate and Hyperlipoproteinemia Type IV
| Article | Year |
|---|---|
Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Clofibrate; Fatty Alcohols; Female; Humans; Hy | 1983 |
Effect of long-term antihypertensive and hypolipidemic treatment on high density lipoprotein cholesterol and apolipoproteins A-I and A-II.
Topics: Antihypertensive Agents; Apolipoproteins; Body Weight; Cholesterol; Clofibrate; Humans; Hyperlipopro | 1980 |
[Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
Topics: Adult; Aged; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Huma | 1981 |
Double-blind study on the activity of plafibride in the treatment of type IV hyperlipoproteinemia.
Topics: Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Humans; Hyperlipo | 1981 |
[Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)].
Topics: Adult; Aged; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Huma | 1982 |
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Female; Fenofibrate; | 1982 |
[Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
Topics: Clofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia | 1980 |
[Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)].
Topics: Adult; Aged; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; | 1980 |
A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins A; Apolipoproteins B; Choleste | 1985 |
40 other studies available for clofibrate and Hyperlipoproteinemia Type IV
| Article | Year |
|---|---|
Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Creatine Kinase; Female; gamma-Glutamyltransfe | 1980 |
[Effect of hypertriglyceridemia and its treatment on tetracycline pharmacokinetics].
Topics: Adult; Clofibrate; Doxycycline; Drug Interactions; Humans; Hyperlipoproteinemia Type IV; Kinetics; M | 1984 |
Clofibrate, caloric restriction, supersaturation of bile, and cholesterol crystals.
Topics: Aged; Bile Acids and Salts; Cholesterol; Clofibrate; Crystallization; Energy Intake; Female; Humans; | 1983 |
[Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Topics: Clofibrate; Drug Combinations; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; H | 1983 |
[Plafibride treatment of hyperlipidemias type II and IV].
Topics: Adult; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperl | 1984 |
The effect of clofibrate on plasma factor and vascular prostacyclin-synthesis.
Topics: Adult; Animals; Aorta; Blood Vessels; Clofibrate; Diet, Atherogenic; Epoprostenol; Humans; Hyperlipo | 1982 |
[Disorders of glucose metabolism and manifestation of diabetes during treatment of endogenous hypertriglyceridemias (author's transl)].
Topics: Adult; Aged; Blood Glucose; Cholesterol; Clofibrate; Diabetes Mellitus; Diet, Reducing; Female; Gluc | 1981 |
[Effect of combination therapy of clofibric acid and nicotinic acid derivatives on fatty acid metabolism in hyperlipoproteinemia].
Topics: Aged; Clofibrate; Clofibric Acid; Drug Therapy, Combination; Fatty Acids; Female; Humans; Hyperlipop | 1982 |
Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Clofibrate; Clofibric Acid; Female; Humans; | 1983 |
Gemfibrozil--a new lipid lowering agent.
Topics: Cholesterol; Clofibrate; Dose-Response Relationship, Drug; Double-Blind Method; Gemfibrozil; Humans; | 1980 |
Platelets intravascular coagulation and fibrinolysis in hyperlipidaemias: relationship to thrombo-embolic complications.
Topics: Adenine Nucleotides; Adult; Blood Coagulation Disorders; Blood Platelets; Clofibrate; Factor XII; Fi | 1980 |
Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Blood Sedimentation; Body Weight; Cholesterol; Ch | 1982 |
Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.
Topics: Apolipoprotein C-I; Apolipoprotein C-II; Apolipoproteins; Apolipoproteins C; Apolipoproteins E; Beza | 1982 |
Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.
Topics: Adipose Tissue; Adult; Bezafibrate; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia | 1982 |
[Effect of clofibric acid on fatty acid metabolism in HLP patients in the 2d half of life].
Topics: Adult; Aged; Cholesterol Esters; Clofibrate; Clofibric Acid; Fatty Acids; Female; Humans; Hyperlipop | 1982 |
[Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; | 1982 |
[Clinical effects and tolerance of etofylline clofibrate].
Topics: Clofibrate; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hy | 1980 |
[Pharmacology of fenofibrate (author's transl)].
Topics: Animals; Cholesterol; Clofibrate; Dogs; Dose-Response Relationship, Drug; Fenofibrate; Humans; Hyper | 1980 |
Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
Topics: Adult; Apolipoproteins; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoprote | 1980 |
Pre- and post-treatment values of HDL cholesterol and total: HDL cholesterol ratio in hyperlipoproteinaemic subjects.
Topics: Cholesterol; Cholesterol, HDL; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipopr | 1981 |
Clinical experience with bezafibrate.
Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Coronary Disease; | 1980 |
[Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
Topics: Adult; Aged; Bile; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperli | 1980 |
[Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
Topics: Blood Glucose; Cholesterol; Clofibrate; Creatinine; Delayed-Action Preparations; Humans; Hyperlipopr | 1980 |
Mechanism of the hypolipemic effect of clofibrate in glucose-fed men.
Topics: Adult; Amino Acids; Clofibrate; Fasting; Fatty Acids, Nonesterified; Glucose; Glycerol; Humans; Hype | 1980 |
The influence of clofibrate on lipid and protein components of very low density lipoproteins in type IV hyperlipoproteinaemia.
Topics: Adult; Aged; Blood Proteins; Cholesterol; Clofibrate; Female; Humans; Hyperlipoproteinemia Type IV; | 1980 |
[Effect of phenofibrate on the blood serum lipid level in hyperlipoproteinemias and its comparison with clofibrate].
Topics: Adult; Aged; Cholesterol; Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyp | 1980 |
The concentration of high density lipoprotein in patients with type IV hyperlipoproteinemia and the effect of clofibrate.
Topics: Adult; Body Weight; Cholesterol; Clofibrate; Humans; Hyperlipoproteinemia Type IV; Lipoproteins, HDL | 1980 |
[The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II; Hyperlip | 1980 |
Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipopro | 1980 |
The effect of etofibrate retard, bezafibrate and procetofen.
Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipopr | 1980 |
[Etofylline clofibrate in the treatment of diabetic dyslipidemia: results of a 6-month period of therapy].
Topics: Clofibrate; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoprotei | 1995 |
Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
Topics: Adult; Aged; Arteriosclerosis; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipopr | 1979 |
[Tolerability and side-effects of bis-(hydroxy-2-ethylthio)-1,10-decane (BS 530) as compared with clofibrate in the therapy of hyperlipemia].
Topics: Clofibrate; Fatty Alcohols; Gastrointestinal Diseases; Headache; Humans; Hyperlipidemias; Hyperlipop | 1979 |
[A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
Topics: Adult; Aged; Bezafibrate; Clofibrate; Clofibric Acid; Dose-Response Relationship, Drug; Female; Huma | 1979 |
[Endogenous hypertriglyceridemia].
Topics: Clofibrate; Coronary Artery Disease; Diet; Exercise Therapy; Female; Humans; Hyperlipoproteinemia Ty | 1992 |
Plafibride treatment and serum lipids in hyperlipoproteinemias.
Topics: Adolescent; Adult; Blood Glucose; Cholesterol; Clofibrate; Clofibric Acid; Diet; Female; Humans; Hyp | 1987 |
Potential use of fenofibrate and other fibric acid derivatives in the clinic.
Topics: Clofibrate; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hy | 1987 |
[Differential use of diet and drugs in dyslipoproteinemias].
Topics: Adult; Clofibrate; Dietary Carbohydrates; Dietary Fats; Female; Humans; Hyperlipoproteinemia Type II | 1985 |
Plasma carnitine and lipid-lowering drugs.
Topics: Carnitine; Cholesterol, HDL; Clofibrate; Female; Humans; Hyperlipidemia, Familial Combined; Hyperlip | 1985 |
Xanthomas and hyperlipidemias.
Topics: Apoproteins; Arteriosclerosis; Cholestasis; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyr | 1985 |